Seneca EIS Portfolio Service investee company OptiBiotix Health has entered into an option agreement with a multinational consumer goods company in relation to its cholesterol reducing product.
Optibiotix are developing compounds to tackle obesity, high cholesterol and diabetes. The terms of the agreement provide the multinational with an option to enter into a definitive agreement following the results of a trial.
Stephen O’Hara, chief executive of OptiBiotix, said: “We are pleased to announce the signing of our first agreement with a global partner for our cholesterol reducing product.”
See the article in full at InsiderMedia.com